Neuromod Appoints New Chief Medical Officer
Dublin, Ireland, 30 July 2014, Neuromod announces the appointment of Dr. Brendan Conlon as Chief Medical Officer for the company. Dr. Brendan Conlon is a leading ENT Surgeon with over 20 years of experience in the areas of vestibulocochlear dysfunction and disease, including hearing loss and tinnitus. Dr. Conlon has conducted research into the pathogenesis of sensorineural hearing loss in animal models in leading US and European University Hospitals, including Duke University, University of Bordeaux, Royal College of Surgeons in Ireland and Trinity College Dublin.
On his appointment, CMO Dr. Conlon said, “There is a real need for credible, evidence based treatments for tinnitus. Audiological and sound-based therapeutic approaches to the treatment of tinnitus have historically disappointed. Multisensory neuromodulation approaches, such as mutebutton®, are a welcome advance, potentially offering a new standard of care for subjective tinnitus. I look forward to helping Neuromod in developing this exciting new approach to tinnitus treatment.”
CEO, Dr. Ross O’Neill said, “I’m delighted to announce the appointment of Dr. Conlon as our Chief Medical Officer. Having such a respected and experienced ENT Surgeon as part of our Management Team will be hugely important in building the credibility of our treatment. Dr. Conlon will bring a wealth of clinical and patient insights to the company. His input will be extremely valuable as we continue to develop our technology.”